Harrow Health price target lowered to $30 from $45 at B. Riley

B. Riley lowered the firm’s price target on Harrow Health to $30 from $45 and keeps a Buy rating on the shares. The analyst views the lower than expected Q4 outlook as disappointing but says Iheezo trends are the “silver lining.”